State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China; Peking-Tsinghua Center for Life Science (CLS), Peking University, Beijing, 100871, China
Auto-generated profile, based on publicly available information
Ningfeng Liu
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China; Peking-Tsinghua Center for Life Science (CLS), Peking University, Beijing, 100871, China
Accurate prediction of drug responses in cancer cell lines (CCLs) and transferable prediction of clinical drug responses using CCLs are two major tasks in personalized medicine. Despite the rapid advancements in existing computational methods for preclinical and clinical cancer drug response (CDR) prediction, challenges remain regarding the generalization of new drugs that are unseen in the training set. Herein, we propose a multimodal fusion deep learning (DL) model called drug-target and single-cell language based CDR (DTLCDR) to predict preclinical and clinical CDRs. The model integrates chemical descriptors, molecular graph representations, predicted protein target profiles of drugs, and cell line expression profiles with general knowledge from single cells. Among these features, a well-trained drug-target interaction (DTI) prediction model is used to generate target profiles of drugs, and a pretrained single-cell language model is integrated to provide general genomic knowledge. Comparison experiments on the cell line drug sensitivity dataset demonstrated that DTLCDR exhibited improved generalizability and robustness in predicting unseen drugs compared with previous state-of-the-art baseline methods. Further ablation studies verified the effectiveness of each component of our model, highlighting the significant contribution of target information to generalizability. Subsequently, the ability of DTLCDR to predict novel molecules was validated through in vitro cell experiments, demonstrating its potential for real-world applications. Moreover, DTLCDR was transferred to the clinical datasets, demonstrating satisfactory performance in the clinical data, regardless of whether the drugs were included in the cell line dataset. Overall, our results suggest that the DTLCDR is a promising tool for personalized drug discovery.
Referential signaling is a fundamental component of social interaction, enabling individuals to direct attention, convey intention, and establish shared understanding. The processing of referential signals operates across multiple levels of neurocognitive systems. First, innate mechanisms rapidly detect socially relevant cues, such as gaze and biological motion, prioritizing social information from infancy. Second, social learning enables the establishment of symbolic conventions in service of referential interactions, implicating the alignment of abstract representations across brains. Third, a deliberative system supports the flexible production and interpretation of referential signals in context by anticipating others’ beliefs and motivation. Despite the diversity and complexity of these processes, recent research has made significant strides in identifying their neural and cognitive bases. Studies indicate that evolutionarily conserved subcortical pathways support early-emerging sensitivity, while cortical networks involved in social reasoning and decision-making underlie acquired and deliberative levels of processing. Future research is needed to clarify how these mechanisms interact across development and how their disruption contributes to neurodevelopmental conditions such as autism spectrum disorder.